Eicosapentaenoic acid intake modulates programmed cell death protein 1 receptors to prevent chronic pain and comorbid depression in mice
Abstract
Background: Fibromyalgia is a frequently treatment-refractory chronic musculoskeletal pain disorder that often results in clinical depression; however, the role of neuroinflammatory signaling in comorbid depression remains unclear, including the contributions of anti-inflammatory omega-3 fatty acids like eicosapentaenoic acid (EPA).
Methods: This study examined the efficacy of EPA ingestion for reducing chronic pain and depression comorbidity (CPDC) in a mouse model established using intermittent cold stress.
Results: Our results showed that oral EPA could alleviate mechanical and thermal hyperalgesia in CPDC mice. The preventive effect of EPA on depressive symptoms in CPDC mice was further confirmed. Western blot and immunofluorescence staining revealed that EPA can inhibit the enhanced neuroinflammatory signaling concomitant with increased astrocyte and microglia activation and elevated levels of inflammatory signaling factors high-mobility group box 1 (HMGB1) and S100B in the CPDC mice. Alternatively, oral EPA can increase the attenuated expression of the pain-inhibiting programmed cell death protein 1 (PD-1) receptor. EPA intake can further alleviate inflammation-associated toll-like receptor 4 (TLR4) and downstream signaling molecules myeloid differentiation primary response 88 (MyD88), TNF receptor associated factor 6 (TRAF6), and activated (phosphorylated) nuclear factor kappa-light-chain-enhancer of activated B cells (pNFκB) in CPDC mouse brain. A similar response…
Read the paper
Related studies
- Promising Sources of Plant-Derived Polyunsaturated Fatty Acids: A Narrative Review
- Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials
- Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials
- The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review
- Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review
- Omega-3 fatty acid nanocarriers: Characterization and potential applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.